Clinical trial
Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased…
NCT00078832 · Queen Mary University of London, Other · Completed
Key facts
| NCT number | NCT00078832 |
|---|---|
| Title | Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer |
| Official title | International Breast Cancer Intervention Study |
| Acronym | IBIS II |
| Lead sponsor | Queen Mary University of London, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | anastrozole, placebo |
| Enrollment | 3,864 |
| Start date | Sep 1, 2003 |
| Primary completion | Dec 1, 2013 |
| Completion | May 31, 2021 |
| First posted | Mar 9, 2004 |
| Last update posted | Oct 6, 2021 |
| Countries | Australia, Belgium, Chile, Denmark, Finland, Germany, Hungary, Ireland, Italy, Malta, Portugal, Switzerland and 2 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: